ClinicalTrials.gg
CompletedNCT03557307PONENTEUpdated Jun 6, 2023Results posted

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

A Phase 3 interventional study of Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 144 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
598
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
7th of 39
598 · median 128
Started
2018
with 1 other
Phase 3
20 of 39
1 open now
Registered
24th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 7th largest by enrollment, is one of 2 that started in 2018, is one of 20 in phase 3, and was the 24th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.

Read the detailed description

This is an open-label, multicenter study designed to evaluate efficacy and safety of reducing daily oral corticosteroid (OCS) use after initiation of 30 mg dose of benralizumab administered subcutaneously (SC) in patients with severe eosinophilic asthma receiving high-dose inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) and OCS with or without additional asthma controller(s).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Severe Asthma
  • Oral Corticosteroids
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Peripheral blood eosinophil count of ≥150 cells/μL assessed by central lab at Visit 1 or ≥ 300 cells/μL in the past 12 months
  2. History of physician diagnosed asthma requiring continuous treatment with high dose ICS (high-dose ICS is budesonide/formoterol HFA ≥640/18 per day or equivalent, fluticasone propionate DPI > 500/day or equivalent, or authorized generics for these products) plus LABA for at least 6 months prior to Visit 1. The ICS and LABA can be contained within a combination product or given by separate inhalers. The ICS can also be given via nebulized solution for inhalation.
  3. Chronic oral therapy equivalent to a daily dose of at least 5 mg of prednisone, for at least 3 continuous months directly preceding Visit 1.
  4. Patient should be on a stable OCS dose for at least 4 weeks prior to Visit 1.
  5. Non-smokers, current smokers or former smokers with a smoking history of \< or =20 pack-years at Visit 1

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than asthma or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts
  2. Known history of allergy or reaction to the study drug formulation
  3. History of anaphylaxis to any biologic therapy
  4. A helminth parasitic infection diagnosed within 24 weeks prior to the date is obtained that has not been treated with, or has failed to respond to, standard of care therapy
  5. Asthma exacerbation requiring use of systemic , or an increase in maintenance dose of OCS, or acute upper/lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to Visit 2 (first benralizumab dose)
  6. A history of known immunodeficiency disorder including history of a positive (HIV) test
  7. (ALT) or aspartate aminotransferase (AST) level ≥3 times the (ULN) confirmed at Visit 1.
  8. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  9. Coincident primary adrenal failure (Addison's disease) or irreversible secondary hypoadrenalism due to another independent cause (e.g. pituitary tumour or its treatment)
  10. Co-existent inflammatory conditions for which chronic OCS doses are part of their maintenance treatment such as Giant Cell Arteritis, Polymyalgia Rheumatica
  11. Exclusion from genetic research may be for any of the exclusion criteria specified in the main study or bone marrow transplant, Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection
  12. Current night-shift workers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
598 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab subcutaneous injection

    Biological: Benralizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Patients Who Achieve 100% Reduction in Daily OCS Dose

    Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

    Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)

  2. Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg

    Patients who achieve 100% reduction or a daily OCS dose of \<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma

    Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)

Secondary outcomes

  1. Patients Who Achieve a Daily OCS of ≤5mg

    Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma

    Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)

  2. Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose

    Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

    Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)

  3. Change From Baseline in Average Daily OCS Dose (mg)

    Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase

    Time frame: Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)

Other outcomes

  1. Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy

    Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

    Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.

  2. Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy

    Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma

    Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.

  3. Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy

    Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

    Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.

  4. Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy

    Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy

    Time frame: from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.

07

Results

Posted Jun 28, 2022
Limitations and caveats
During COVID-19 pandemic, for ongoing patients, patient dosing, and scheduled visits are inevitably impacted, but the primary endpoint was not impacted.

Participant flow

705 participants provided informed consent and were assigned a unique enrollment number prior to screening. Of the 705 patients screened, 598 (84.8%) were eligible to receive Benralizumab 30 mg and entered the study. All 598 (100%) patients received the study drug. 195 of the 538 patients who completed the main study treatment enrolled into PONENTE Long Term Follow Up Substudy.

Period 1: To End of OCS Reduction Phase
Participant flow — Period 1: To End of OCS Reduction Phase
MilestoneBenra 30 mg
Started598
Completed563
Not completed35
Withdrew: Withdrawal by subject10
Withdrew: Adverse event7
Withdrew: Protocol violation6
Withdrew: Lost to follow-up5
Withdrew: Other3
Withdrew: Death2
Withdrew: Failure to meet inclusion/exclusion criteria2
Period 2: Maintenance Phase
Participant flow — Period 2: Maintenance Phase
MilestoneBenra 30 mg
Started563
Completed536
Not completed27
Withdrew: Adverse event4
Withdrew: Death3
Withdrew: Lost to follow-up2
Withdrew: Pregnancy2
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject2
Withdrew: Other3
Period 3: Long Term Follow up Substudy
Participant flow — Period 3: Long Term Follow up Substudy
MilestoneBenra 30 mg
Started195
Asthma treatment as per healthcare provider discretion195
>=50% any biologic78
>=50% benra69
Completed195
Not completed0

Outcome measures

PrimaryPatients Who Achieve 100% Reduction in Daily OCS Dose

Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

Time frame:
Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Reported as:
Count of participants · Participants
Patients Who Achieve 100% Reduction in Daily OCS Dose
ParticipantsBenra 30 mg
Patients Who Achieve 100% Reduction in Daily OCS Dose376
Statistical analysis
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 62.9 · 95% CI 58.86 to 66.76Percentage of patients who achieved 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
PrimaryPatients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg

Patients who achieve 100% reduction or a daily OCS dose of \<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma

Time frame:
Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Reported as:
Count of participants · Participants
Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg
ParticipantsBenra 30 mg
Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg490
Statistical analysis
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 81.9 · 95% CI 78.62 to 84.94Percentage of patients who achieve 100% reduction or a daily OCS dose of \<=5mg, if reason for no further OCS reduction is Adrenal Insufficiency, that are sustained over at least 4 weeks without worsening of asthma
SecondaryPatients Who Achieve a Daily OCS of ≤5mg

Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma

Time frame:
Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Reported as:
Count of participants · Participants
Patients Who Achieve a Daily OCS of ≤5mg
ParticipantsBenra 30 mg
Patients Who Achieve a Daily OCS of ≤5mg547
Statistical analysis
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 91.5 · 95% CI 88.94 to 93.58Percentage of patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma
SecondaryPatients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose

Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

Time frame:
Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Reported as:
Count of participants · Participants
Patients Who Achieve a ≥90%, ≥75%, and ≥50% Reduction in Daily OCS Dose
ParticipantsBenra 30 mg
≥90% reduction383
≥75% reduction412
≥50% reduction489
Statistical analysis
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 64.0 · 95% CI 60.06 to 67.90Percentage of patients who achieve \>=90% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 68.9 · 95% CI 65.02 to 72.59Percentage of patients who achieve \>=75% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 81.8 · 95% CI 78.44 to 84.79Percentage of patients who achieve \>=50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma
SecondaryChange From Baseline in Average Daily OCS Dose (mg)

Change from baseline in average daily OCS dose (mg) from start of OCS reduction to end of the OCS reduction phase

Time frame:
Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)
Reported as:
Mean · mg
Change From Baseline in Average Daily OCS Dose (mg)
mgBenra 30 mg
Change From Baseline in Average Daily OCS Dose (mg)-8.50 (-9.10 to -7.90)
Statistical analysis
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage change from baseline: -76.92 · 95% CI -79.90 to -73.94Percentage change from baseline in daily OCS dose at the end of OCS reduction phase
Other pre-specifiedPatients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy

Patients who achieve 100% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

Time frame:
from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Reported as:
Count of participants · Participants
Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy
ParticipantsAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
Patients Who Achieve 100% Reduction in Daily OCS Dose From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy1386054
Other pre-specifiedPatients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy

Patients who achieve a daily OCS dose of ≤5 mg (regardless of reason for no further OCS reduction), that are sustained over at least 4 weeks without worsening of asthma

Time frame:
from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Reported as:
Count of participants · Participants
Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy
ParticipantsAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
Patients Who Achieve a Daily OCS Dose of ≤5 mg at the End of the Long Term Follow up Substudy1777265
Other pre-specifiedPatients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy

Patients who achieve a ≥90%, ≥75%, and ≥50% reduction in daily OCS dose that are sustained over at least 4 weeks without worsening of asthma

Time frame:
from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Reported as:
Count of participants · Participants
Patients Who Achieve ≥90%, ≥75%, ≥50% or >0% OCS Reduction From Main Study Baseline OCS Dose to the End of the Long Term Follow up Substudy
ParticipantsAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
>=90% reduction1416155
>=75% reduction1516458
>=50% reduction1727164
>0% reduction1757265
Other pre-specifiedChange in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy

Change in average daily OCS dose (mg) from main study baseline to the end of the long term follow up substudy

Time frame:
from main study baseline to the end of the long term follow up substudy, an average of approximate 922 days.
Reported as:
Mean · mg
Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy
mgAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
Change in Daily OCS Dose (mg) From Main Study Baseline to the End of the Long Term Follow up Substudy-10.01 (-11.26 to -8.76)-10.28 (-12.16 to -8.41)-10.8 (-12.85 to -8.75)

Adverse events

Collected over Main study: From first dose of study drug until end of study, with an average of 405 days. Substudy: on-study period, between the date of informed consent for the substudy and the last available visit or contact for a patient, with an average of 18 days.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg5/598 (0.8%)89/598 (14.9%)181/598 (30.3%)
Asthma Treatment as Per Healthcare Provider Discretion0/195 (0%)0/195 (0%)0/195 (0%)
>=50% Any Biologic0/78 (0%)0/78 (0%)0/78 (0%)
>=50% Benra0/69 (0%)0/69 (0%)0/69 (0%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventBenra 30 mgAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
AsthmaRespiratory, thoracic and mediastinal disorders23/5980/1950/780/69
PneumoniaInfections and infestations11/5980/1950/780/69
InfluenzaInfections and infestations5/5980/1950/780/69
Acute myocardial infarctionCardiac disorders4/5980/1950/780/69
SepsisInfections and infestations3/5980/1950/780/69
Angina unstableCardiac disorders2/5980/1950/780/69
Cardiac arrestCardiac disorders2/5980/1950/780/69
IleusGastrointestinal disorders2/5980/1950/780/69
Chronic sinusitisInfections and infestations2/5980/1950/780/69
DiverticulitisInfections and infestations2/5980/1950/780/69
Most frequent other events
Most frequent other events
EventBenra 30 mgAsthma Treatment as Per Healthcare Provider Discretion>=50% Any Biologic>=50% Benra
NasopharyngitisInfections and infestations64/5980/1950/780/69
Influenza like illnessGeneral disorders33/5980/1950/780/69
HeadacheNervous system disorders29/5980/1950/780/69
Viral upper respiratory tract infectionInfections and infestations28/5980/1950/780/69
Upper respiratory tract infectionInfections and infestations25/5980/1950/780/69
HypertensionVascular disorders21/5980/1950/780/69
SinusitisInfections and infestations19/5980/1950/780/69

Baseline characteristics

Full analysis set

Age, Continuous
Age, Continuous(years)Benra 30 mg
Mean53.3 ± 13.59
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30 mg
Female383
Male215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benra 30 mg
White475
Black or African American26
Asian29
Native Hawaiian or other Pacific Islander1
American Indian or Alaska Native46
Other12
08

Study locations

144 sites
  • Research Site
    Flagstaff, Arizona 86001, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Winter Park, Florida 32789-4681, United States
  • Research Site
    Albany, Georgia 31707, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Savannah, Georgia 31405, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Georgetown, Kentucky 40324, United States
  • Research Site
    Lakeside Park, Kentucky 41017, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Saint Paul, Minnesota 55101, United States
  • Research Site
    Saint Louis, Missouri 63156, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Buenos Aires, C1121ABE, Argentina
  • Research Site
    Caba, C1012AAR, Argentina
  • Research Site
    Cap. Fed, 1280, Argentina
  • Research Site
    Ciudad Autónoma de Bs. As., 1426, Argentina
  • Research Site
    Ciudad Autónoma de Buenos Aire, C1440BRR, Argentina
  • Research Site
    Florencio Varela, 1888, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mendoza, M5500GIP, Argentina
  • Research Site
    Monte Grande, 1842, Argentina
  • Research Site
    Ranelagh, 1886, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Erpent, 5101, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Botucatu, 18618-970, Brazil
  • Research Site
    Londrina, 86057-970, Brazil
  • Research Site
    Maringa, 87015-000, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Salvador, 40060-330, Brazil
  • Research Site
    Santo Andre, 09060-650, Brazil
  • Research Site
    Santo Andre, 09080-110, Brazil
  • Research Site
    Sorocaba, 18040-425, Brazil
  • Research Site
    Uberlandia, 38411-186, Brazil
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Vancouver, CA V5Z 4E1, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Mississauga, Ontario L5A 3V4, Canada
  • Research Site
    Ottawa, Ontario K1H 1E4, Canada
  • Research Site
    Toronto, Ontario M4V 1R2, Canada
  • Research Site
    Quebec, G1V 4W2, Canada
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Bogota, 110221, Colombia
  • Research Site
    Cali, 76001000, Colombia
  • Research Site
    Cartagena, 130013, Colombia
  • Research Site
    Floridablanca, 681004, Colombia
  • Research Site
    Manizales, 17001, Colombia
  • Research Site
    Medellin, 5001000, Colombia
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Ålborg, 9000, Denmark
  • Research Site
    ANGERS Cedex 9, 49933, France
  • Research Site
    Besancon Cedex, 25030, France
  • Research Site
    Colmar Cedex, 68024, France
  • Research Site
    Marseille, 13300, France
  • Research Site
    NICE Cedex 01, 06001, France
  • Research Site
    Orléans, 45067, France
  • Research Site
    Reims, 51092, France
  • Research Site
    Suresnes Cedex, 92151, France
  • Research Site
    Tours, 37000, France
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Berlin, 13187, Germany
  • Research Site
    Darmstadt, 64283, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Köln, 51069, Germany
  • Research Site
    Leipzig, 04207, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Milano, 20162, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Palermo, 90129, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Roma, 00185, Italy
  • Research Site
    Sassari, 07100, Italy
  • Research Site
    Tradate, 21049, Italy
  • Research Site
    Del. Cuauhtemoc, 06700, Mexico
  • Research Site
    Durango, 43080, Mexico
  • Research Site
    Guadalajara, 44100, Mexico
  • Research Site
    Guadalajara, 44130, Mexico
  • Research Site
    Mérida, 97070, Mexico

Showing the first 100 of 144 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, Harrison T, Jackson DJ, Price D, Lugogo N, Kreindler J, Burden A, de Giorgio-Miller A, Padilla K, Martin UJ, Garcia Gil E. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4. Erratum In: Lancet Respir Med. 2021 Dec;9(12):e114. doi: 10.1016/S2213-2600(21)00464-1. PubMed 34619104 ↗
  • Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3):00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul. PubMed 31579676 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Apr 2021, 32 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
Jun 15, 2018
StartActual
Aug 1, 2018
Primary completionActual
Apr 16, 2021
CompletionActual
Mar 24, 2022
Results first posted
Jun 28, 2022
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03557307
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Aug 1, 2018
Primary completion
Apr 16, 2021
Completion
Mar 24, 2022
Results posted
Jun 28, 2022
Last update
Jun 6, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion